Personalis, Inc. (PSNL), a genomics company based in Menlo Park, California, focuses primarily on providing cancer genomics services to support the global biopharmaceutical industry's development of personalized cancer treatments. The team at Personalis integrates multidimensional tumor profiling data and information derived from proprietary databases to understand essential cancer biology. This integration provides insights that allow physicians and researchers to devise comprehensive, personalized treatment plans for cancer patients.
Personalis was established in 2011 by a team of genomics veterans from Stanford University who were passionate about making a significant contribution to the field of precision oncology. The company went public on the Nasdaq under the ticker symbol "PSNL" in June 2019.
The company's accreditation and certification as a CAP-accredited and CLIA-certified laboratory underscore its commitment to maintaining the highest standards of clinical laboratory practices. This accreditation enables Personalis to offer its services to both commercial customers and clinical trials.
The key offering from Personalis is the ACE ImmunoID platform. It is a next-generation sequencing (NGS) based platform that provides comprehensive insights into the tumor, microenvironment, and the body's immune response, enabling clinicians and researchers to tailor treatments more effectively and efficiently. The breadth and depth of data generated by this platform have significant implications for the development of individualized immunotherapies.
Personalis's Immunogenomics ID provides biopharmaceutical companies with comprehensive immunogenomics profiling for biomarker discovery, clinical trials, and translational research. It's also vital for the development of new oncology drugs. Moreover, under its NeXT Platform, Personalis offers services such as advanced analytics, data interpretation, and translational informatics to aid in better understanding of cancer genomics.
Notably, Personalis's customer base includes renowned entities that span biopharmaceutical companies, nonprofits, clinical researchers, and leading academic institutions. The company is also a provider to the U.S. Department of Veterans Affairs' Million Veteran Program, which aims to create one of the world's largest medical databases to study the role of genes in health and disease.
While Personalis faces competition from other genomics companies, its unique focus on oncology, robust technological platform, and commitment to research and development sets it apart. It remains at the forefront of helping to unlock the secrets of the human genome to improve cancer outcomes, a testament to its innovative spirit and mission to revolutionize cancer treatment. In the future, Personalis aims to continue expanding the development and application of its pioneering platforms in pursuit of its goal to redefine cancer care.